Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
Artios Pharma has raised $115.0M in total funding. The most recent round was Series D. The last funding was announced in November 2025.
Artios Pharma's investors include RA Capital Management, Schroders Capital, Sofinnova Partners, AbbVie, EQT Life Sciences.
Artios Pharma is headquartered in Cambridge, United Kingdom.
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
Artios Pharma is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Artios Pharma — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/artios-pharma. Accessed July 20, 2026.
VCBacked. (2025). Artios Pharma — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/artios-pharma
{{cite web |title=Artios Pharma — Funding & Investors |url=https://www.vcbacked.co/company/artios-pharma |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated